GC Biopharma Corp
15
5
8
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
33%
5 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Role: lead
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
Role: lead
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
Role: lead
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Role: lead
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Role: lead
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Role: lead
Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study
Role: lead
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Role: lead
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
Role: lead
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ
Role: lead
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions
Role: lead
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions
Role: lead
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
Role: lead
IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
Role: collaborator
Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor
Role: collaborator
All 15 trials loaded